Quinn Opportunity Partners LLC Sells 48,306 Shares of BioNTech SE (NASDAQ:BNTX)

Quinn Opportunity Partners LLC lowered its position in BioNTech SE (NASDAQ:BNTX - Free Report) by 11.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 356,194 shares of the company's stock after selling 48,306 shares during the quarter. BioNTech makes up approximately 2.7% of Quinn Opportunity Partners LLC's portfolio, making the stock its 4th biggest position. Quinn Opportunity Partners LLC owned about 0.15% of BioNTech worth $40,588,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in BNTX. State Street Corp raised its holdings in BioNTech by 2.0% in the 3rd quarter. State Street Corp now owns 155,867 shares of the company's stock worth $18,512,000 after purchasing an additional 3,014 shares in the last quarter. XTX Topco Ltd bought a new position in BioNTech in the 3rd quarter worth about $459,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of BioNTech during the third quarter valued at approximately $718,000. Vestcor Inc purchased a new position in shares of BioNTech in the third quarter worth $784,000. Finally, Exome Asset Management LLC bought a new position in BioNTech during the 3rd quarter valued at about $4,104,000. Institutional investors own 15.52% of the company's stock.

BioNTech Stock Down 3.3 %

Shares of NASDAQ BNTX traded down $3.34 during midday trading on Tuesday, reaching $99.00. 972,555 shares of the company's stock traded hands, compared to its average volume of 859,669. The company has a market cap of $23.76 billion, a price-to-earnings ratio of -47.14 and a beta of 1.07. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. BioNTech SE has a one year low of $76.53 and a one year high of $131.49. The stock's 50 day simple moving average is $104.24 and its 200-day simple moving average is $111.51.

Remove Ads

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.24 billion. During the same period last year, the business posted $1.90 earnings per share. The firm's revenue was down 19.5% compared to the same quarter last year. On average, analysts predict that BioNTech SE will post -3.88 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BNTX has been the topic of several analyst reports. BMO Capital Markets lifted their price target on shares of BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 11th. Morgan Stanley cut their target price on shares of BioNTech from $145.00 to $139.00 and set an "overweight" rating for the company in a report on Tuesday, March 11th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $171.44 price target on shares of BioNTech in a research note on Tuesday, March 11th. Truist Financial began coverage on shares of BioNTech in a research note on Friday, January 10th. They issued a "buy" rating and a $172.00 price objective for the company. Finally, HC Wainwright decreased their target price on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Three investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $143.44.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.